Drugs / GSK2800528
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01899755 | Jul 2013 → Apr 2014 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2800528 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01899755 ↗ |
| Action | Inhibit | “anti-tumor necrosis factor (TNF) alpha” NCT01899755 ↗ |
| Modality | Monoclonal antibody | “human anti-tumor necrosis factor (TNF) alpha monoclonal antibody (mAb)” NCT01899755 ↗ |
| Route | Subcutaneous | “administered at 3 different dose levels by subcutaneous injection” NCT01899755 ↗ |
| Target | TNF | “anti-tumor necrosis factor (TNF) alpha” NCT01899755 ↗ |